Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
4.520
-0.200 (-4.24%)
At close: Oct 24, 2024, 4:00 PM
4.570
+0.050 (1.11%)
After-hours: Oct 24, 2024, 5:10 PM EDT
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $43.19M in the quarter ending June 30, 2024, a decrease of -11.72%. This brings the company's revenue in the last twelve months to $168.77M, down -10.99% year-over-year. In the year 2023, Adaptive Biotechnologies had annual revenue of $170.28M, down -8.11%.
Revenue (ttm)
$168.77M
Revenue Growth
-10.99%
P/S Ratio
4.08
Revenue / Employee
$238,034
Employees
709
Market Cap
666.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Standard BioTools | 136.30M |
Simulations Plus | 66.98M |
Tango Therapeutics | 42.51M |
Lexicon Pharmaceuticals | 3.64M |
Oculis Holding AG | 969.29K |
Opthea | 261.86K |
ADPT News
- 15 days ago - Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewsWire
- 2 months ago - Adaptive Announces IVDR Certification for clonoSEQ® in European Union - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024 - GlobeNewsWire
- 5 months ago - Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress - GlobeNewsWire
- 5 months ago - Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire